Oruka Therapeutics, Inc. — Director's Dealing 2013

Jan 28, 2013

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ARCA biopharma, Inc. (ABIO)
CIK: 0000907654
Period of Report: 2013-01-25

Reporting Person: BRISTOW MICHAEL R (Director, President and CEO, 10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2013-01-25	Common Stock	P	1069290	$.4676	Acquired	1069290	Indirect

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2013-01-25	Common stock warrants (right to buy)	$.3801	P	748503	Acquired	2020-01-25	Common Stock (748503)	Indirect

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	834495	Indirect
Common Stock	280071	Direct

Footnotes

F1: The warrants are fully vested and exercisable upon issuance and have a contractual term of 7 years.